MVA 85A: all 25 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) InfectionTerminatedNCT02532036Phase 1Results posted
• Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)CompletedNCT01151189Phase 2Results posted
• A Study of MVA85A in Healthy InfantsCompletedNCT00953927Phase 2Results posted
• EMaBS TB Vaccine StudyCompletedNCT03681860Phase 1/2
• Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African AdolescentsCompletedNCT02178748Phase 2
• Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector ImmunityCompletedNCT01954563Phase 1
• Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated AdultsCompletedNCT01879163Phase 1
• Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy AdultsCompletedNCT01829490Phase 1
• Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85ACompletedNCT01683773Phase 1
• Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost VaccinationCompletedNCT01650389Phase 2
• A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85ACompletedNCT01194180Phase 1
• Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal RouteCompletedNCT01181856Phase 1
• A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIVCompletedNCT00731471Phase 1
• A Study of MVA85A in Healthy Children and InfantsCompletedNCT00679159Phase 2
• A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85ACompletedNCT00653770Phase 1
• A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or BothCompletedNCT00480558Phase 1
• Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI VaccinesCompletedNCT00480454Phase 1
• A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCGCompletedNCT00465465Phase 1
• Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape TownCompletedNCT00460590Phase 1
• Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.CompletedNCT00456183Phase 1
• A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCGCompletedNCT00427830Phase 1
• A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month PreviouslyCompletedNCT00427453Phase 1
• A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian VolunteersCompletedNCT00423839Phase 1
• A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.CompletedNCT00423566Phase 1
• The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIVCompletedNCT00395720Phase 1

← MVA 85A overview